Neuroblastoma Research and Treatments

Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid.

The paper investigates RA's limited effect on primary neuroblastoma tumors but efficacy in clearing bone marrow cells, identifying BMP signaling as a key determinant of cell fate and RA sensitivity.

A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma

This study shows neuroblastoma cells are hypersensitive to PLK4 inhibitor RP-1664 due to dual mechanisms of centriole loss and amplification, leading to cell death.

Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets

This paper identifies cell state-dependent and -independent immunotherapeutic targets in neuroblastoma by analyzing subtype-specific gene expression and validating targets through experimental methods.

Frequent lncRNA-derived fusions in pediatric neuroblastoma identified by LncFusion: potential biomarker and therapeutic implications

The paper identifies over 900 lncRNA-derived fusions in pediatric neuroblastoma using LncFusion, revealing their potential as biomarkers and therapeutic targets.

The MYCN/Aurora-A complex is a cyclin activating kinase for CDK12

This study identifies Aurora-A as a CDK12-activating kinase in neuroblastoma, showing its role in transcription termination and tumor growth suppression.

Noncoding RNA elements within MYCN mRNA are potent autonomous drivers of oncogenesis.

This study shows that full-length MYCN mRNA with noncoding elements drives oncogenesis more effectively than MYCN protein alone, revealing new insights into cancer mechanisms.

Epac activation reduces trans-endothelial migration of undifferentiated neuroblastoma cells and cellular differentiation with a CDK inhibitor further enhances Epac effect.

A comparative network analysis of high-risk MYCN amplified and high-risk MYCN non-amplified neuroblastoma patients

This study compares PPI networks between high-risk MYCN amplified and non-amplified neuroblastoma patients to identify predictive biomarkers.

Diphenyleneiodonium chloride inhibits MYCN-amplified neuroblastoma by targeting MYCN induced mitochondrial alterations

This study identifies diphenyleneiodonium chloride as a compound that targets MYCN-amplified neuroblastoma by inducing proteasomal degradation of MYCN and reversing mitochondrial alterations.

Copy-number dosage regulates telomere maintenance and disease-associated pathways in neuroblastoma

The paper identifies gene dosage effects on telomere maintenance and disease pathways in neuroblastoma using genomic and transcriptomic data from 115 tumors.

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma

This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.

5UTR translational inhibition of neuroblastoma dependency factors using the CR-1-31-B rocaglate

This study evaluates CR-1-31-B's effects on neuroblastoma, showing reduced tumor growth and revealing translational inhibition of key dependencies and synergistic effects with CHK1 inhibition.

Novel sex-biased outcomes in neuroblastoma are associated with distinct gene expression and chromosomal loss patterns.

The paper identifies sex-biased outcomes in neuroblastoma, showing female patients with MYCN non-amplified high-risk disease have worse survival than males, linked to H19/DLK1 expression and chromosome 11q retention.

DKK1, a negative regulator of Wnt signaling, is a novel inducer of neuroblastoma differentiation

This study shows DKK1 inhibits neurosphere formation and promotes neuronal differentiation in SHSY5Y cells, with synergistic effects when combined with retinoic acid.

Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma

BPTF cooperates with MYCN and MYC to link neuroblastoma cell cycle control to epigenetic cellular states

This study shows BPTF works with MYCN and MYC to control cell cycle and epigenetic states in neuroblastoma, linking it to poor prognosis and therapeutic potential.

The MYCN oncoprotein and helicases DDX17 and DDX5 have opposite effects on the production of chimeric transcripts in neuroblastoma cells

This study shows that MYCN and helicases DDX17/DDX5 have opposing roles in transcription termination and chimeric transcript production in neuroblastoma, with MYCN inhibiting helicase activity and promoting harmful RNA molecules.

5-hydroxymethylcytosine profiling of cell-free DNA identifies bivalent genes that are prognostic of survival in high-risk neuroblastoma.

The paper identifies bivalent genes in neuroblastoma cell-free DNA associated with poor prognosis in high-risk patients.

Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma

The paper identifies adrenergic and mesenchymal signatures in cell-free DNA 5-hmC profiles and shows their correlation with metastatic burden in neuroblastoma patients.

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma

This study identifies BARD1 germline variants associated with reduced BARD1 expression and DNA repair defects in neuroblastoma, showing haploinsufficiency and increased genomic instability.

Clonal evolution during metastatic spread in high-risk neuroblastoma

This study traces clonal evolution in high-risk neuroblastoma using genomic data from 470 samples, showing metastatic clones can remain dormant and later cause relapses.

Germline pathogenic variants in 786 neuroblastoma patients

This study identifies 13.9% of neuroblastoma patients with pathogenic germline variants in cancer predisposition genes, associated with worse survival and enriched in DNA repair genes like BARD1.

Neural crest-related NXPH1/α-NRXN signaling opposes neuroblastoma malignancy by inhibiting metastasis

The paper identifies a transcriptional signature distinguishing low- and high-risk neuroblastomas and shows that NXPH1/-NRXN signaling inhibits metastasis while promoting tumor growth.

Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma

This study identifies somatic structural variations in neuroblastoma, showing their enrichment in neurodevelopmental genes and the tumor suppressor role of SHANK2.

Epigenomic profiling of neuroblastoma cell lines

The paper provides ChIP-Seq and ATAC-Seq data for MYCN, MYC, and histone marks in neuroblastoma cell lines to study gene regulation and enhancer dynamics.

A deep neural network approach to predicting clinical outcomes of neuroblastoma patients

This paper develops a deep neural network approach for predicting neuroblastoma patient outcomes using graph-based feature extraction, achieving higher accuracy than traditional models.

IRE1α is critical for kaempferol induced neuroblastoma differentiation

This study shows kaempferol induces neuroblastoma differentiation via the IRE1-XBP1 pathway by activating IRE1's endoribonuclease activity.